This study included 1504 patients with atrial fibrillation and indication for elective electrical cardioversion who were randomized to rivaroxaban (n = 1002) versus Marevan (n = 502).
The safety end point, major bleeding occurred in 0.61% of rivaroxaban group versus 0.8% of Marevan (95% IC 0.21-2.67, p = NS). The rate of stroke, embolic events, myocardial infarction or cardiovascular death occurred in 0.51% of the Rivaroxaban group versus 1.02% of Marevan group (p = ns).
Ricardo Cappato
2014-09-02
Original title: The X-VERT Trial: A comparison of oral rivaroxaban once daily with dose-adjusted Vitamin K Antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion. X-VeRT study.
